✦ LIBER ✦

Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy

✍ Scribed by Yao-Yu Hsieh; Cheng-Hwai Tzeng; Ming-Huang Chen; Po-Min Chen; Wei-Shu Wang

Book ID: 114703200
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 306 KB
Volume: 103
Category: Article
ISSN: 1347-9032
DOI: 10.1111/j.1349-7006.2012.02225.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Epidermal growth factor receptor gene co

Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab

✍ Carla Campanella; Marcella Mottolese; Anna Cianciulli; Angela Torsello; Roberta 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 456 KB

Insulin-like growth factor 1 expression

Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan

✍ Mario Scartozzi; Alessandra Mandolesi; Riccardo Giampieri; Chiara Pierantoni; Fo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 245 KB

## Abstract Seventy to 40% of K‐RAS wild type colorectal tumors does not seem to benefit from treatment with antiepidermal growth factor receptor (anti‐EGFR) monoclonal antibodies. Recent data suggested that in presence of IGF‐1 system, altered activation colorectal cancer cells may escape anti‐EGF

Promising biomarkers for predicting the

Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A systematic review with meta-analysis

✍ Yang, Zu-Yao; Wu, Xin-Yin; Huang, Ya-Fang; Di, Meng-Yang; Zheng, Da-Yong; Chen, 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 French ⚖ 937 KB

Treatment of patients with KRAS wild typ

Treatment of patients with KRAS wild type advanced colorectal cancer with 5-fluorouracil (5-FU) or 5-FU plus an epidermal growth factor receptor inhibitor (cetuximab) based on a comprehensive geriatric assessment

✍ Wedding, U.; Messina, C.; Mauer, M.; Pallis, A.; Harrison, J.; Wildiers, H.; Pee 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 50 KB

Analysis of HER-3, insulin growth factor

Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab

✍ Scartozzi, M.; Giampieri, R.; Maccaroni, E.; Mandolesi, A.; Giustini, L.; Silva, 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 123 KB

PP 22 Analysis of HER-3, insulin-growth

PP 22 Analysis of HER-3, insulin-growth factor-1 (IGF-1), nuclear factor k-B (NF-kB) and epidermal growth factor receptor (EGFR) gene copy number (GCN) in the prediction of clinical outcome for K-RAS wild type colorectal cancer patients receiving irinotecan–cetuximab

✍ M. Scartozzi; R. Giampieri; E. Maccaroni; A. Mandolesi; L. Giustini; R.R. Silva; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 57 KB